Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity - Jin, Dan; Tran, Nguyen; Thomas, Nagheme; Tran, David D. (PloS one, 2019)
Keywords: Aminopyridines - pharmacology; Biology and Life Sciences; Brain cancer; Brain research; Breast; Breast cancer; Cancer; Cancer therapies; Carboplatin; Cell cycle; Cell Cycle Checkpoints - drug effects; Cell Death - drug effects; Cell division; Cell Line, Tumor; Combination drug therapy; Cyclin-dependent kinase 4; Cyclin-Dependent Kinase 4 - antagonists & inhibitors; Cyclin-Dependent Kinase 4 - metabolism; Cyclin-Dependent Kinase 6 - antagonists & inhibitors; Cyclin-Dependent Kinase 6 - metabolism; Cytotoxic agents; Cytotoxicity; Drug Liberation; Drug Therapy, Combination; Drugs; Humans; Inhibitors; Kinases; Lung cancer; Medical research; Medical schools; Medicine; Medicine and Health Sciences; Metastasis; Neurosurgery; Oncology; Palbociclib; Piperazines - pharmacology; Proteins; Purines - pharmacology; Pyridines - pharmacology; Regulatory approval; Ribociclib; S Phase - drug effects; Schedules; Senescence; Solid tumors; Targeted cancer therapy; Toxicity; Tumor cell lines; Tumors; United States--US